|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
|
|
Jan 3
|
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
|
|
Jan 2
|
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
|
|
Jan 2
|
5 Large Drug Stocks to Keep An Eye On in the New Year
|
|
Dec 30
|
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?
|
|
Oct 12
|
AstraZeneca PLC (AZN): A Top Holding in George Soros’s Portfolio
|
|
Oct 9
|
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Oct 8
|
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
|
|
Oct 8
|
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
|
|
Oct 8
|
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
|
|
Oct 8
|
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
|
|
Oct 7
|
5 Large Drug Stocks to Watch From a Thriving Industry
|
|
Oct 7
|
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
|
|
Oct 7
|
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
|
|
Oct 7
|
AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
|
|
Aug 8
|
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
|
|
Aug 7
|
Top Analyst Reports for AstraZeneca, TotalEnergies & ConocoPhillips
|
|
Aug 6
|
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
|
|
Aug 5
|
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
|